Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment

BACKGROUND: Daily oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevents human immunodeficiency (HIV) among people who inject drugs (PWID). Despite rising HIV incidence and injection drug use (IDU), PrEP use remains low and there is limited research...

Descripción completa

Detalles Bibliográficos
Autores principales: Brokus, Christopher, Kattakuzhy, Sarah, Gayle, Britt, Narayanan, Shivakumar, Davis, Ashley, Cover, Amelia, Eyasu, Rahwa, Ebah, Emade, Ogbumbadiugha-Weekes, Onyinyechi, Hoffmann, Jennifer, Silk, Rachel, Stevens, Jasmine, Mount, Julia, Gannon, Catherine, Nussdorf, Laura, Mathur, Poonam, Bijole, Phyllis, Jones, Miriam, Kier, Randy, Sternberg, David, Greenblatt, Aaron, Weintraub, Eric, Masur, Henry, Kottilil, Shyamasundaran, Rosenthal, Elana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849288/
https://www.ncbi.nlm.nih.gov/pubmed/35187191
http://dx.doi.org/10.1093/ofid/ofab658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849288/
https://www.ncbi.nlm.nih.gov/pubmed/35187191
http://dx.doi.org/10.1093/ofid/ofab658

Ejemplares similares